论文信息 - Biosimilar Ranibizumab and Innovator Ranibizumab-Immunogenicity Assessment and Its Impact on Safety and Efficacy. - 字舞流文

Biosimilar Ranibizumab and Innovator Ranibizumab-Immunogenicity Assessment and Its Impact on Safety and Efficacy.

B. Kuppermann | Ashish Sharma | Nilesh Kumar

[1] N. Bressler,et al. Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics , 2022, JAMA ophthalmology.

[2] A. Loewenstein,et al. Approved biosimilar ranibizumab—a global update , 2022, Eye.

[3] B. Kuppermann,et al. Fear of safety compromise with biosimilar anti-VEGF—perception or truth , 2022, Eye.

[4] A. Loewenstein,et al. Brolucizumab and immunogenicity , 2020, Eye.

[5] A. Loewenstein,et al. Ophthalmic biosimilars and biologics—role of endotoxins , 2019, Eye.

[6] A. Loewenstein,et al. Biotherapeutics and immunogenicity: ophthalmic perspective , 2019, Eye.